30
Participants
Start Date
February 29, 2004
Primary Completion Date
December 31, 2008
Study Completion Date
November 30, 2010
arsenic trioxide
Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
gemtuzumab ozogamicin
Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
Cleveland Clinic Taussig Cancer Center, Cleveland
University of Michigan
OTHER
National Cancer Institute (NCI)
NIH
The Cleveland Clinic
OTHER